Skip to content

Study · Case report or series · n = 1 · 2026

3 results

Ischemic Colitis Associated With Tirzepatide Therapy in a Young Female Patient: A Case Report.

Sekhon S, Kahlon I, Latson W

Cureus13 Jan 2026

PMID41694961 (opens in a new tab)PMCIDPMC12896725 (opens in a new tab)DOI10.7759/cureus.101437 (opens in a new tab)PepBankPUB-41694961
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

Tirzepatide has been approved for the management of obesity, obstructive sleep apnea, and type 2 diabetes mellitus; while gastrointestinal side effects are commonly seen, ischemic colitis has been only rarely described. We present the case of a 32-year-old woman with no prior medical history who developed hematochezia and abdominal pain after six weeks of tirzepatide therapy for weight loss. Laboratory evaluation showed neutrophilic leukocytosis without anemia or electrolyte abnormalities, and stool studies were negative for infection. A CT of the abdomen and pelvis excluded obstruction or wall thickening but incidentally revealed hepatic steatosis and adnexal lesions. Colonoscopy demonstrated patchy erosions, erythema, and ulcerations in the sigmoid and descending colon, with biopsy confirming ischemic colitis. She was managed conservatively with bowel rest, intravenous fluids, and close monitoring, with stable hemoglobin and complete resolution of symptoms. Although ischemic colitis is more typically linked to vascular disease, hypotension, or vasoconstrictive drugs, recent reports have suggested an association with glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide and tirzepatide. The temporal relationship with tirzepatide initiation, absence of infection, and confirmatory histology strongly support drug-induced ischemia in this case, underscoring the importance of clinician awareness of this rare but significant complication in patients presenting with rectal bleeding or abdominal pain while on incretin-based therapy.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    A 32-year-old woman developed hematochezia and abdominal pain after six weeks of tirzepatide therapy for weight loss.

    In plain wordsOne young woman developed rectal bleeding and belly pain after six weeks of tirzepatide taken for weight loss.

    Peptide
    Tirzepatide
    Outcome
    Not applicableHematochezia and abdominal pain
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    We present the case of a 32-year-old woman with no prior medical history who developed hematochezia and abdominal pain after six weeks of tirzepatide therapy for weight loss.
  2. 02HumanCase report or seriesSafety outcome

    A woman with ischemic colitis after tirzepatide had neutrophilic leukocytosis without anemia or electrolyte abnormalities.

    In plain wordsOne woman with bowel injury after tirzepatide had a raised white blood cell count, without anemia.

    Peptide
    Tirzepatide
    Outcome
    IncreaseNeutrophilic leukocytosis
    Study

    n = 1

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Laboratory evaluation showed neutrophilic leukocytosis without anemia or electrolyte abnormalities
    1 context sentence
    Summary · context
    We present the case of a 32-year-old woman with no prior medical history who developed hematochezia and abdominal pain after six weeks of tirzepatide therapy for weight loss.
  3. 03HumanCase report or seriesSafety outcome

    In a 32-year-old woman on tirzepatide, colonoscopy and biopsy confirmed ischemic colitis of the sigmoid and descending colon.

    In plain wordsIn one young woman on tirzepatide, a camera exam and biopsy confirmed bowel injury from poor blood supply.

    Peptide
    Tirzepatide
    Outcome
    Not applicableIschemic colitis confirmed by colonoscopy and biopsy
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Colonoscopy demonstrated patchy erosions, erythema, and ulcerations in the sigmoid and descending colon, with biopsy confirming ischemic colitis.
    1 context sentence
    Summary · context
    We present the case of a 32-year-old woman with no prior medical history who developed hematochezia and abdominal pain after six weeks of tirzepatide therapy for weight loss.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.